An Open-label, Multicenter, Ascending Dose Study of the Tolerability and Safety of Recombinant Human Acid Sphingomyelinase (rhASM) in Patients With Acid Sphingomyelinase Deficiency (ASMD)

Trial Profile

An Open-label, Multicenter, Ascending Dose Study of the Tolerability and Safety of Recombinant Human Acid Sphingomyelinase (rhASM) in Patients With Acid Sphingomyelinase Deficiency (ASMD)

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Olipudase alfa (Primary)
  • Indications Niemann-Pick disease type B
  • Focus Adverse reactions
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 04 Jun 2015 According to a Genzyme Corporation media release, olipudase alfa has been granted Breakthrough Therapy designation by the U.S. FDA for the treatment of Niemann-Pick disease type B. The designation is supported by data from this trial.
    • 12 Feb 2015 According to a Genzyme media release, results were presented at the Lysosomal Disease Network's WORLD Symposium 2015.
    • 12 Feb 2015 Results were published in a Genzyme media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top